GTAEXS617

Phase 2

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Advanced Solid Tumor

Clinical Trial

Last updated: 12/4/2025

Developer

RXRX

Recursion Pharmaceuticals, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

Familial Adenomatous Polyposis

AXIN1 Gene Mutation

Cerebral Cavernous Malformation

Unresectable